Valuation: Futura Medical plc

Market Cap 3.24M 4.33M 3.79M 3.48M 6.15M 412M 6.25M 41.78M 16.24M 203M 16.26M 15.91M 699M P/E 2024
77.2x
P/E 2025 -0.4x
Enterprise Value -158K -211K -184K -169K -299K -20.07M -304K -2.03M -790K -9.86M -791K -774K -33.99M EV / Sales 2024
6,428,637x
EV / Sales 2025 1,815,433x
Free-Float
83.88%
Yield 2024 *
-
Yield 2025 -
1 day+233.33%
1 month-22.22%
3 months-41.67%
6 months-49.28%
Current year-49.28%
1 week 0
Extreme 0.0014
0.01
1 month 0
Extreme 0.0014
0.03
Current year 0
Extreme 0.0014
0.04
1 year 0
Extreme 0.0013
0.2
3 years 0
Extreme 0.0013
0.88
5 years 0
Extreme 0.0013
2.7
10 years 0
Extreme 0.0013
2.7
Manager TitleAgeSince
Chief Executive Officer 56 2025-08-07
Director of Finance/CFO 46 2018-02-19
Chief Tech/Sci/R&D Officer 74 2016-11-15
Director TitleAgeSince
Director/Board Member 74 2016-03-31
Director/Board Member 46 2018-02-19
Chairman 69 -
Change 5-day change 1-year change 3-year change Capi.($)
+233.33%-.--% - - 4.33M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +25.92%+8.57%+54.64%+148.04% 27.28B
Weighted average by Cap. +2.47%+6.47%+59.06%+137.71%

Financials

2024 2025
Net sales 13.93 18.6 16.26 14.94 26.41 1.77K 26.81 179.36 69.73 870.38 69.8 68.31 3K 1.7 2.27 1.98 1.82 3.22 215.73 3.27 21.85 8.49 106.04 8.5 8.32 365.41
Net income 1.29M 1.73M 1.51M 1.39M 2.45M 164M 2.49M 16.65M 6.47M 80.81M 6.48M 6.34M 278M -9.07M -12.11M -10.59M -9.73M -17.2M -1.15B -17.47M -117M -45.42M -567M -45.47M -44.49M -1.95B
Net Debt -6.6M -8.81M -7.7M -7.08M -12.51M -839M -12.7M -84.96M -33.03M -412M -33.06M -32.35M -1.42B -3.4M -4.54M -3.97M -3.65M -6.45M -433M -6.55M -43.81M -17.03M -213M -17.05M -16.68M -733M
Logo Futura Medical plc
Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.
Employees
13
Date Price Change Volume
26-06-30 US$0.007000 +233.33% 90,440
26-06-29 US$0.002100 -70.00% 600
26-06-26 US$0.007000 -53.18% 7,000

Annual profits - Rate of surprise